What's Mounjaro, and how does it actually work?

The myth worth correcting first: Mounjaro is not 'just another GLP-1'

Most weight-loss injections you'll read about target a single pathway. Semaglutide (Wegovy) activates GLP-1 receptors, which signal fullness and slow the rate at which the stomach empties. Tirzepatide does that too, but it also activates GIP receptors, a second gut-hormone system involved in energy balance and how the body handles fat tissue. The combination appears to produce a stronger appetite-suppressing effect than either pathway alone. That's not a marketing claim; it's the conclusion drawn from head-to-head trial data. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks in adults with obesity who did not have diabetes. A single receptor versus two isn't a subtle difference, it's the mechanistic reason the two medicines sit in separate categories, and why the conditions tirzepatide is licensed to treat have expanded beyond weight management to include type 2 diabetes in its own right.

The practical upshot for someone reading this page: Mounjaro is not interchangeable with Wegovy, and it is not related to Ozempic beyond sharing a broad drug class. They do different things at the receptor level.

What the pen looks like and what the treatment schedule actually involves

Each Mounjaro KwikPen is a slim, auto-injector about the size of a chunky marker pen, pre-filled and ready to use. Treatment starts at the 2.5 mg strength, a dose whose job is to let your body adjust to tirzepatide rather than to drive significant weight loss in itself. The 2.5 mg pen sits in the fridge alongside everything else until the morning of your weekly injection; you inject into the abdomen, thigh, or upper arm, rotating sites each time. From there, the prescriber guides titration, typically moving up through 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg in roughly four-week steps, based on tolerance and how you're responding. The specifics of each dose volume are worth understanding before you start. When it arrives, the pen comes in plain, unbranded packaging via a DPD tracked delivery, you'll get a notification on your phone the morning of delivery, like any other parcel.

Detailed advice on injection timing, rotating sites, what to do if you miss a week, and when to contact your prescriber is set out in the Patient Information Leaflet inside the box. For dosing decisions (including whether to move up or stay at a given strength) the prescriber who reviewed your consultation is the right person to ask, not a forum.

Who Mounjaro is licensed for in the UK

The UK licence covers adults with a BMI of 30 or above, and adults with a BMI of 27 or above who have at least one weight-related condition, for example, high blood pressure, high cholesterol, type 2 diabetes, prediabetes, or obstructive sleep apnoea. BMI thresholds are reduced by 2.5 kg/m² for some ethnic backgrounds under UK guidance. None of that guarantees approval: a prescriber assesses the full picture, including your medical history, current medicines, and any conditions that might make tirzepatide unsuitable.

Mounjaro is not licensed for anyone under 18, and it is not recommended during pregnancy, while breastfeeding, or when trying to conceive. People with a history of medullary thyroid carcinoma, MEN2 syndrome, or acute pancreatitis need to discuss their situation with a specialist before tirzepatide is considered. The guidance on what to do while you're on Mounjaro covers the practical safety habits that matter once treatment starts. You can explore the full clinical picture on our Mounjaro treatment page, which sets out eligibility in more detail alongside the NHS access context.

Side effects and what the MHRA monitoring means for you

The most commonly reported side effects are gastrointestinal: nausea, constipation, diarrhoea, indigestion, and burping tend to be most noticeable after starting or after a dose increase, and most people find they settle within a week or two. Fatigue, headache, dizziness, and injection-site reactions are also reported. These are described fully on the NHS tirzepatide medicines page, which is a reliable first reference alongside the leaflet in your pack.

The Black Triangle (▼) on Mounjaro's packaging signals that the MHRA is collecting enhanced post-market safety data, a routine requirement for medicines approved in recent years, not a flag that something is wrong. One specific serious risk worth knowing: severe, persistent abdominal pain that spreads to the back, especially alongside vomiting, should prompt an urgent call to 111 or A&E. Acute pancreatitis is a rare but recognised risk with GLP-1-class medicines, and NICE's guidance on tirzepatide at TA1026 addresses monitoring considerations for prescribers. Suspected side effects can be reported directly via the MHRA's Yellow Card scheme.

If you're weighing up whether this medicine fits your situation, the cost context page covers what private prescriptions typically include, and what to be cautious about when prices look unusually low.